drugset / Trial / NCT00666705

A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects

NCT00666705

Phase 4 Completed 18 enrolled ViiV Healthcare Pfizer · collab
Non-randomizedSingle-groupOpen-label

Summary

An open label study to evaluate an interaction between maraviroc and raltegravir in healthy subjects.

Timeline

Start
2008-02
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified 300 mg
Subject Raltegravir Other / unclassified 400 mg

Indications

No indication recorded.